Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical ...

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma ...

THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM PHILADELPHIA, PA / ACCESS Newswire / ...

Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least ...

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire ...
Taiwan News

Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of ...

SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access ...

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Medicus Pharma Ltd. (Nasdaq: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is ...

Sol-Gel Technologies Ltd.: Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug's commercial potentialIn September 2025 ...

Maxim Group Reaffirms Buy on Medicus Pharma Ltd (MDCX) With $20 Target

Medicus Pharma Ltd (NASDAQ:MDCX) is one of the Canadian penny stocks to buy right now. On November 18, Maxim Group analyst ...

Tennessee's Education Freedom Scholarships challenged

A lawsuit filed in Davidson County Chancery Court challenges the constitutionality of Tennessee's Education Freedom ...
TipRanks on MSN

Medicus Pharma Seeks FDA Priority Voucher for Innovative Skin Cancer Treatment

An announcement from Medicus Pharma Ltd ( ($MDCX) ) is now available. Medicus Pharma Ltd. has submitted an FDA Commissioner’s National Priority ...

I'm a Celebrity... Get Me Out of Here! - The line-up in full

TV personality Jack Osbourne, comedian Ruby Wax and model and presenter Kelly Brook are among the celebrities who will brave the Australian jungle in the forthcoming series of I'm a Celebrity...Get Me ...

Medicus Pharma stock jumps after FDA priority voucher application

The FDA’s Commissioner’s National Priority Voucher (CPNV) program, announced in June 2025, offers an expedited review process that could shorten the typical 10-12 month review time to just 1-2 months.